BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8103950)

  • 1. The product of the c-erbB-2 proto-oncogene as a target for diagnosis and therapy in breast cancer.
    Dean CJ; Allan S; Eccles S; McFarlane C; Styles J; Valeri M; Sandle J; Bakir A; Sacks N
    Year Immunol; 1993; 7():182-92. PubMed ID: 8103950
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.
    Allan SM; Dean C; Fernando I; Eccles S; Styles J; McCready VR; Baum M; Sacks N
    Br J Cancer; 1993 Apr; 67(4):706-12. PubMed ID: 8097104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.
    Park JW; Stagg R; Lewis GD; Carter P; Maneval D; Slamon DJ; Jaffe H; Shepard HM
    Cancer Treat Res; 1992; 61():193-211. PubMed ID: 1360232
    [No Abstract]   [Full Text] [Related]  

  • 4. C-erbB-2 expression in squamous cell carcinoma of the head and neck.
    Field JK; Spandidos DA; Yiagnisis M; Gosney JR; Papadimitriou K; Stell PM
    Anticancer Res; 1992; 12(3):613-9. PubMed ID: 1377893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer.
    Horiguchi J; Iino Y; Takei H; Yokoe T; Ishida T; Morishita Y
    Oncology; 1994; 51(1):47-51. PubMed ID: 7903441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-erbB-2 oncogene as a prognostic marker in breast cancer.
    Perren TJ
    Br J Cancer; 1991 Mar; 63(3):328-32. PubMed ID: 1672251
    [No Abstract]   [Full Text] [Related]  

  • 7. c-erbB-2 gene product-like expression in urothelial carcinomas of the human bladder. Its value as a prognostic indicator in superficial tumors.
    Serio G
    Pathologica; 1991; 83(1086):413-20. PubMed ID: 1686491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioimmunoscintigraphy in patients with ovarian cancer.
    Kalofonos HP; Karamouzis MV; Epenetos AA
    Acta Oncol; 2001; 40(5):549-57. PubMed ID: 11669325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
    Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
    Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-erbB-2 gene in human head and neck carcinoma.
    Craven JM; Pavelic ZP; Stambrook PJ; Pavelic L; Gapany M; Kelley DJ; Gapany S; Gluckman JL
    Anticancer Res; 1992; 12(6B):2273-6. PubMed ID: 1363518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
    Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast mucin and associated antigens in diagnosis and therapy.
    Peterson JA; Ceriani RL
    Adv Exp Med Biol; 1994; 353():1-8. PubMed ID: 7527177
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance.
    Blin N; Kardaś I; Welter C; Ryś J; Niezabitowski A; Limon J; Seitz G
    Oncology; 1993; 50(6):408-11. PubMed ID: 7901823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of erbB-2/neu levels in tissue.
    Paik S; King CR; Simpson S; Lippman ME
    Methods Enzymol; 1991; 198():290-300. PubMed ID: 1677445
    [No Abstract]   [Full Text] [Related]  

  • 17. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
    Börjesson PK; Postema EJ; de Bree R; Roos JC; Leemans CR; Kairemo KJ; van Dongen GA
    Oral Oncol; 2004 Sep; 40(8):761-72. PubMed ID: 15288829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
    De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O
    Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of tumor antigens with monoclonal antibodies: immunopathology and immunodiagnosis.
    Neville AM
    Curr Opin Immunol; 1991 Oct; 3(5):674-8. PubMed ID: 1684511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head and neck squamous cell carcinoma cell lines as a model system for the study of oncogene expression during tumor progression and metastasis.
    Gallick GE; Sacks PG; Maxwell SA; Steck PA; Gutterman JU
    Prog Clin Biol Res; 1986; 212():97-111. PubMed ID: 3012576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.